English

Bioretec Ltd – Managers’ transactions

Report this content

Bioretec Ltd      Managers’ transactions   25 February 2022 at 3.00 p.m. EET

Bioretec Oy - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Johanna Salko
Position: Chief Financial Officer
Issuer: Bioretec Oy
LEI: 7437008736AG7HY51K13
6 / 7
Notification type: INITIAL NOTIFICATION
Reference number: 10516/5/4
____________________________________________
Transaction date: 2022-02-22
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: Bioretec Oy, optio-ohjelma 2020-1, A-C
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
Transaction details
(1): Volume: 750000 Unit price: 0 EUR
(2): Volume: 750000 Unit price: 0 EUR
(3): Volume: 500000 Unit price: 0 EUR
Aggregated transactions
(3): Volume: 2000000 Volume weighted average price: 0 EUR

Further enquiries

Tomi Numminen, Chairman of the Board, tel. +358 40 581 2132

Timo Lehtonen, CEO, tel. +358 50 433 8493

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of bioresorbable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery.  The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.  

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong bioresorbable materials for enhanced surgical outcomes. The RemeOs™ implants are resorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. With the U.S. and EU market authorization for the first RemeOs™ product expected in 2022, Bioretec is positioning itself to enter the addressable USD 7 billion global orthopedic trauma market and become a game changer in surgical possibilities. Better Healing – Better Life. www.bioretec.com.

Subscribe